Gardner M O, Owen J, Skelly S, Hauth J C
Department of Obstetrics and Gynecology, University of New Mexico, Albuquerque 87131-5286, USA.
J Reprod Med. 1996 Dec;41(12):903-6.
To determine if tocolytic therapy with indomethacin is associated with an increased risk of neonatal complications in infants born prior to 32 weeks' gestation.
We performed a retrospective matched cohort study of infants born between 24 and 31(6)/7 weeks' gestation. The 62 cases (indomethacin treatment) and the 62 controls were matched by week of gestation, prenatal betamethasone exposure and multifetal gestation.
The mean gestational age of the two groups was 28.5 +/- SD weeks. The median total dose of indomethacin was 425 mg, the median treatment duration was three days, and the median interval from the last dose of indomethacin until delivery was one day. There was no significant difference between the groups in the incidence of necrotizing enterocolitis, intraventricular hemorrhage, patent ductus arteriosis, sepsis or neonatal death.
The use of indomethacin for tocolysis was not associated with an increased risk of neonatal complications in infants born between 24 and 31(6)/7 weeks' gestation.
确定使用吲哚美辛进行宫缩抑制治疗是否会增加妊娠32周前出生婴儿发生新生儿并发症的风险。
我们对妊娠24至31(6)/7周出生的婴儿进行了一项回顾性匹配队列研究。62例(吲哚美辛治疗组)和62例对照组按孕周、产前倍他米松暴露情况和多胎妊娠情况进行匹配。
两组的平均孕周为28.5±标准差周。吲哚美辛的总剂量中位数为425mg,治疗持续时间中位数为3天,从最后一剂吲哚美辛到分娩的间隔时间中位数为1天。两组在坏死性小肠结肠炎、脑室内出血、动脉导管未闭、败血症或新生儿死亡的发生率上无显著差异。
在妊娠24至31(6)/7周出生的婴儿中,使用吲哚美辛进行宫缩抑制与新生儿并发症风险增加无关。